Medical Oncology最新文献_第2页

Letter to the editor: comment on "Chitosan-loaded piperlongumine nanoparticles and kaempferol enhance the anti-cancer action of doxorubicin in targeting of Ehrlich solid adenocarcinoma: in vivo and in silico modeling study". 致编辑的信：关于 "壳聚糖负载哌隆明纳米粒子和山柰酚增强多柔比星针对艾氏实体腺癌的抗癌作用：体内和硅学模型研究 "的评论。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-29 DOI: 10.1007/s12032-024-02488-1

Adane Desta Gonemo, Ajay Prakash Pasupulla, Murali Santhoshkumar

引用次数: 0

Letter to the editor: Comment on "Anti-cancer potential of casein and its derivatives: novel strategies for cancer treatment". 致编辑的信：关于 "酪蛋白及其衍生物的抗癌潜力：癌症治疗的新策略 "的评论。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-23 DOI: 10.1007/s12032-024-02482-7

Ramya Rajendiran, Murali Santhoshkumar

引用次数: 0

The potential of lenvatinib in breast cancer therapy. 来伐替尼在乳腺癌治疗中的潜力。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-22 DOI: 10.1007/s12032-024-02477-4

Yuefeng Shang, Tong Liu, Wenjing Wang

{"title":"The potential of lenvatinib in breast cancer therapy.","authors":"Yuefeng Shang, Tong Liu, Wenjing Wang","doi":"10.1007/s12032-024-02477-4","DOIUrl":"10.1007/s12032-024-02477-4","url":null,"abstract":"Breast cancer, as a highly prevalent cancer among women, is one of the main causes of female mortality due to cancer. There is a need for more treatment options to improve the survival time of breast cancer patients. Metastasis to distant organs is a standard indicator of advanced breast cancer and a primary cause of breast cancer mortality, making the control of breast cancer metastasis crucial. Targeted therapy, with its advantages of precision, high effectiveness, and minimal side effects, has garnered significant attention as a hot research topic in breast cancer treatment. Among these therapies, anti-angiogenic therapy aim to inhibit tumor angiogenesis, control tumor growth, and reduce metastasis. Additionally, anti-angiogenic therapy can restructure the tumor vasculature, enhancing the effectiveness of other anti-cancer drugs. Lenvatinib, an orally available small molecule multi-targeted tyrosine kinase inhibitor, exerts its anti-tumor effects mainly by inhibiting tumor angiogenesis and tumor cell proliferation. It has been approved for the treatment of thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. Due to its multi-targeted nature, lenvatinib not only has direct anti-tumor effects but also possesses immunomodulatory activity, which can enhance the tumor immune response. This makes it a promising candidate for a broad range of cancers. Recent studies have explored the role of lenvatinib in breast cancer, including its various mechanisms of action and its use as a monotherapy or in combination to control breast cancer progression. This review will summarize the molecular mechanisms and research progress of lenvatinib in breast cancer treatment, discussing its potential applications and therapeutic prospects in managing breast cancer.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2-methoxyestradiol sensitizes tamoxifen-resistant MCF-7 breast cancer cells via downregulating HIF-1α. 2-甲氧基雌二醇通过下调 HIF-1α 使抗他莫昔芬的 MCF-7 乳腺癌细胞变得敏感。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-21 DOI: 10.1007/s12032-024-02471-w

Yasmin M Attia, Hamada Ahmed Mokhlis, Ahmed Ismail, Ahmed S Doghish, Mohamed H Sobhy, Sherif S Hassanein, Walaa A El-Dakroury, Amr D Mariee, Salama A Salama, Marwa Sharaky

{"title":"2-methoxyestradiol sensitizes tamoxifen-resistant MCF-7 breast cancer cells via downregulating HIF-1α.","authors":"Yasmin M Attia, Hamada Ahmed Mokhlis, Ahmed Ismail, Ahmed S Doghish, Mohamed H Sobhy, Sherif S Hassanein, Walaa A El-Dakroury, Amr D Mariee, Salama A Salama, Marwa Sharaky","doi":"10.1007/s12032-024-02471-w","DOIUrl":"10.1007/s12032-024-02471-w","url":null,"abstract":"The clinical studies for breast cancer (BC) are now assessing the efficacy of 2-Methoxyestradiol (2-ME), a naturally occurring derivative of estradiol. Our study aimed to explore the potential of combining the 2-ME and tamoxifen (TAM) on sensitization of TAM-resistant cells using LCC2 the TAM-resistant cells as a model and comparing the results to the sensitive cells MCF-7. Sulphorhodamine-B (SRB) assay is used to examine the 2-ME chemo-sensitizing impact on the cytotoxicity of TAM on LCC2 cells. Colorimetric assay kits were used to assess the level of the apoptosis-related markers caspases 3, Bcl2, and Bax in cell lysate. Hypoxia-inducible factor 1 alpha (HIF-1α) expression was measured using western blotting. Total cholesterol and triglyceride (TG) levels were examined colorimetrically, using the BIOLABO kit. The use of 2-ME enhanced the cytotoxic effects of TAM and effectively reversed TAM resistance. This was achieved by inhibiting the expression of HIF-1α, while concurrently increasing the levels of apoptotic marker caspase-3, as well as the pro-apoptotic protein Bax. Additionally, there was a reduction in the levels of Bcl2, an anti-apoptotic protein. Furthermore, a reduction in TG and cholesterol levels was noted. Our findings show that HIF-1α plays an important role in TAM resistance and that suppression of HIF-1α by 2-ME-mediated sensitization of BC-resistant cells to TAM. Therefore, the concurrent administration of TAM/2-ME might potentially serve as a viable therapeutic approach to address TAM resistance and enhance the overall therapy efficacy for patients with BC.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunomodulation aspects of gut microbiome-related interventional strategies in colorectal cancer. 结直肠癌肠道微生物相关干预策略的免疫调节方面。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-20 DOI: 10.1007/s12032-024-02480-9

Makan Cheraghpour, Nayeralsadat Fatemi, Mahdi Shadnoush, Ghazaleh Talebi, Sascha Tierling, Luis G Bermúdez-Humarán

{"title":"Immunomodulation aspects of gut microbiome-related interventional strategies in colorectal cancer.","authors":"Makan Cheraghpour, Nayeralsadat Fatemi, Mahdi Shadnoush, Ghazaleh Talebi, Sascha Tierling, Luis G Bermúdez-Humarán","doi":"10.1007/s12032-024-02480-9","DOIUrl":"10.1007/s12032-024-02480-9","url":null,"abstract":"Colorectal cancer (CRC), the third most common cancer worldwide, develops mainly due to the accumulation of genetic and epigenetic changes over many years. Substantial evidence suggests that gut microbiota plays a significant role in the initiation, progression, and control of CRC, depending on the balance between beneficial and pathogenic microorganisms. Nonetheless, gut microbiota composition by regulating the host immune response may either promote or inhibit CRC. Thus, modification of gut microbiota potentially impacts clinical outcomes of immunotherapy. Previous studies have indicated that therapeutic strategies such as probiotics, prebiotics, and postbiotics enhance the intestinal immune system and improve the efficacy of immunotherapeutic agents, potentially serving as a complementary strategy in cancer immunotherapy. This review discusses the role of the gut microbiota in the onset and development of CRC in relation to the immune response. Additionally, we focus on the effect of strategies manipulating gut microbiome on the immune response and efficacy of immunotherapy against CRC. We demonstrate that manipulation of gut microbiome can enhance immune response and outcomes of immunotherapy through downregulating Treg cells and other immunosuppressive cells while improving the function of T cells within the tumor; however, further research, especially clinical trials, are needed to evaluate its efficacy in cancer treatment.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142004546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2023 ACS - LANA lymphedema summit forward momentum; future steps in lymphedema management. 2023 ACS - LANA 淋巴水肿峰会前进的动力；淋巴水肿管理的未来步骤。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-19 DOI: 10.1007/s12032-024-02476-5

Elizabeth Campione, David Doubblestein

引用次数: 0

A new therapeutic strategy for luminal A-breast cancer treatment: vulpinic acid as an anti-neoplastic agent induces ferroptosis and apoptosis mechanisms. 治疗管腔 A 型乳腺癌的新策略：硫辛酸作为一种抗肿瘤药物可诱导铁变态反应和细胞凋亡机制。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-19 DOI: 10.1007/s12032-024-02473-8

Ayşe Hale Alkan, Mine Ensoy, Demet Cansaran-Duman

{"title":"A new therapeutic strategy for luminal A-breast cancer treatment: vulpinic acid as an anti-neoplastic agent induces ferroptosis and apoptosis mechanisms.","authors":"Ayşe Hale Alkan, Mine Ensoy, Demet Cansaran-Duman","doi":"10.1007/s12032-024-02473-8","DOIUrl":"10.1007/s12032-024-02473-8","url":null,"abstract":"Breast cancer is a common invasive tumor in women, and the most common subtype of breast cancer is luminal A. Hormonal therapies are the primary treatment for luminal A, but treatment options are limited. Vulpinic acid (VA), a lichen compound, inhibited cancer cells. Here, we aimed to reveal the functional role and mechanism of VA in luminal A breast cancer. Experiments associated with the ferroptosis mechanism were performed to reveal the role of vulpinic acid on luminal A-breast cancer and the underlying mechanisms. The results showed that VA induced the ferroptosis pathway by decreasing glutathione (GSH) levels while increasing lipid reactive oxygen species (ROS), lipid peroxidation (MDA), and intracellular Fe2+ levels in MCF-7 cells. After treatment of MCF-7 cells with VA, the ferroptosis-related gene expression profile was significantly altered. Western blot analysis showed that GPX4 protein levels were down-regulated and LPCAT3 protein levels were up-regulated after VA treatment. Our study suggests that apoptosis and ferroptosis act together in VA-mediated tumor suppression in MCF-7 breast cancer cells. These findings suggest that VA, an anti-neoplastic agent, could potentially treat luminal A targeted breast cancer via the ferroptosis pathway.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Moscatilin, a potential therapeutic agent for cancer treatment: insights into molecular mechanisms and clinical prospects. 麝香草苷--一种潜在的癌症治疗药物：对分子机制和临床前景的见解。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-17 DOI: 10.1007/s12032-024-02467-6

Rita Silva-Reis, Vera L M Silva, Susana M Cardoso, Izabela Michalak, Mirosława Püsküllüoğlu, Daniela Calina, Javad Sharifi-Rad

{"title":"Moscatilin, a potential therapeutic agent for cancer treatment: insights into molecular mechanisms and clinical prospects.","authors":"Rita Silva-Reis, Vera L M Silva, Susana M Cardoso, Izabela Michalak, Mirosława Püsküllüoğlu, Daniela Calina, Javad Sharifi-Rad","doi":"10.1007/s12032-024-02467-6","DOIUrl":"10.1007/s12032-024-02467-6","url":null,"abstract":"Moscatilin, a bibenzyl derivative from the Dendrobium genus, has been traditionally used in Chinese medicine. Recent studies suggest its potential as a powerful anticancer agent due to its diverse pharmacological properties.This review aims to consolidate current research on moscatilin's anticancer mechanisms, structure-activity relationships, and therapeutic potential to assess its viability for clinical use. A literature search was performed in PubMed/MedLine, Scopus, and Web of Science.The search focused on \"cancer,\" \"moscatilin,\" \"anticancer,\" \"bioactivity,\" \"dendrobium,\" and \"pharmacological properties.\" Relevant studies on molecular mechanisms, preclinical and clinical efficacy, and bioavailability were reviewed. Moscatilin exhibits significant anticancer effects in lung, breast, colorectal, and pancreatic cancers. It induces apoptosis via the JNK/SAPK pathway, inhibits cell proliferation, and suppresses metastasis. Structure-activity relationship studies reveal that phenolic groups and a two-carbon bridge are crucial for its efficacy. Additionally, moscatilin shows good bioavailability and a favorable safety profile, with low toxicity to healthy cells. Moscatilin demonstrates considerable potential as an anticancer agent, targeting multiple cancer progression pathways. Further clinical trials are essential to confirm its therapeutic efficacy and safety in humans.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer/testis antigen expression and co-expression patterns in gastroesophageal adenocarcinoma. 胃食管腺癌中癌症/睾丸抗原的表达和共表达模式

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-14 DOI: 10.1007/s12032-024-02475-6

Sukumar Kalvapudi, Akhil Goud Pachimatla, R J Seager, Jeffrey Conroy, Sarabjot Pabla, Sarbajit Mukherjee

{"title":"Cancer/testis antigen expression and co-expression patterns in gastroesophageal adenocarcinoma.","authors":"Sukumar Kalvapudi, Akhil Goud Pachimatla, R J Seager, Jeffrey Conroy, Sarabjot Pabla, Sarbajit Mukherjee","doi":"10.1007/s12032-024-02475-6","DOIUrl":"10.1007/s12032-024-02475-6","url":null,"abstract":"Gastroesophageal adenocarcinoma (GEAC) poses a significant challenge due to its poor prognosis and limited treatment options. Recently, Cancer/testis antigens (CTAs) have emerged as potential therapy targets due to their high expression in tumor cells and their immunogenic nature. We aimed to explore the expression and co-expression of CTAs in GEAC. We analyzed 63 GEAC patients initially and validated our findings in 329 patients from The Cancer Genome Atlas (TCGA) database. CTA expression was measured after RNA sequencing, while clinical information, including survival outcomes and treatment details, was collected from an institutional database. Co-expression patterns among CTAs were determined using Spearman correlation analysis. The majority of the study cohort were male (87%), Caucasian (94%), and had stage IV disease (64%). CTAs were highly prevalent, ranging from 58 to 19%. The MAGE gene family showed the highest expression, consistent across both cohorts. The correlation matrix revealed a distinct cluster of significantly co-expressed genes, including MAGEA3, NY-ESO-1, and others (0.27 ≤ r ≤ 0.73). Survival analysis revealed that individual CTAs were associated with poorer survival outcomes in patients not receiving immunotherapy while showing potential for improved survival in those undergoing immunotherapy, although these findings lacked robust reliability. Our study provides a comprehensive characterization of CTA expression and co-expression in GEAC. The strong correlation among CTAs like MAGE, NY-ESO-1, and GAGE suggests a potential for therapies targeting multiple CTAs simultaneously. Further research, including prospective trials, is warranted to assess the prognostic value of CTAs and their suitability as therapeutic targets.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letters to editor regarding the article "P4HA2 contributes to head and neck squamous cell carcinoma progression and EMT through PI3K/AKT signaling pathway". 致编辑的信，内容涉及文章 "P4HA2通过PI3K/AKT信号通路促进头颈部鳞状细胞癌的进展和EMT"。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-13 DOI: 10.1007/s12032-024-02436-z

K L G Afeeza, S Balachandran, S Muthamizh, E Dilipan

{"title":"Letters to editor regarding the article \"P4HA2 contributes to head and neck squamous cell carcinoma progression and EMT through PI3K/AKT signaling pathway\".","authors":"K L G Afeeza, S Balachandran, S Muthamizh, E Dilipan","doi":"10.1007/s12032-024-02436-z","DOIUrl":"10.1007/s12032-024-02436-z","url":null,"abstract":"We have read the original article titled \"P4HA2 contributes to head and neck squamous carcinoma progression and EMT through PI3K/AKT signaling pathway\" by Yan-Ling Wu et al., which was published in the Medical Oncology journal, with great interest. This study provides valuable insights into the involvement of P4HA2 in the progression of head and neck squamous cell carcinoma (HNSCC), highlighting its potential as an oncogenic factor that promotes epithelial-mesenchymal transition (EMT), motility, invasion, and proliferation of cancer cells through the PI3K/AKT signaling pathway. While this work enhances our understanding of the role of P4HA2 in HNSCC, there are certain aspects that remain unexplored. These areas could be further investigated in future research to obtain a more comprehensive understanding. Specifically, the study did not investigate other signaling pathways or molecular mechanisms through which P4HA2 may impact the development of HNSCC. By exploring these molecular pathways, it may be possible to identify specific targets for pharmaceutical intervention to inhibit the production of P4HA2. Examining these aspects in future research would significantly contribute to our understanding of the role of P4HA2 in HNSCC and its potential as a therapeutic target. We appreciate the authors for their significant contribution and eagerly await future studies that expand upon these findings.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141971372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0